FDA Approves Ovarian Cancer Maintenance Treatment

Source: U.S. Food and Drug Administration

Mar 28, 2017

The U.S. Food and Drug Administration has granted approval of Zejula (niraparib) to Tesaro, Inc. The drug is a maintenance treatment for adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have shrunk after platinum-based chemotherapy. The FDA 

These types of cancer affect the tissue covering the ovary or the lining of the fallopian tube or abdominal wall. According to the National Cancer Institute, more than 22,000 women will be diagnosed of these cancers, with more than 14,000 patients dying.

According to the FDA, Zejula is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme involved in repairing damaged DNA, which makes the DNA inside the cancerous cells less likely to be repaired, leading to a slow-down or stoppage of tumor growth.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments